Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $9.3100 (-2.92%) ($8.9300 - $9.4900) on Thu. Jun. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 16.95% (three month average) | RSI | 29 | Latest Price | $9.3100(-2.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.4% a day on average for past five trading days. | Weekly Trend | ADAP declines -5.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XBI(22%) XLRE(22%) IWC(21%) DRIV(20%) IBB(19%) | Factors Impacting ADAP price | ADAP will decline at least -8.475% in a week (0% probabilities). TLT(-13%) BNDX(-11%) TIP(-10%) VXX(-9%) FXI(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -8.475% (StdDev 16.95%) | Hourly BBV | 0 () | Intraday Trend | -1.7% | | | |
|
Resistance Level | $10.51 | 5 Day Moving Average | $9.65(-3.52%) | 10 Day Moving Average | $9.9(-5.96%) | 20 Day Moving Average | $10.51(-11.42%) | To recent high | -23.1% | To recent low | 80.1% | Market Cap | $1.439b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |